

PET/CT

CLINICAL APPLICATIONS: ONCOLOGY

Scheduling 000.000.0000

Company Name or Logo

10

9

8

7

6

5

4

3

2

1

0

BLADDER: 78815

- Determine extent of local, regional and distant disease

BREAST: 78815

- Staging of Internal Mammary Nodes
- Exclude local recurrence of disease
- Evaluate response to treatment
- Accurately Identify the Extent of Metastatic Disease

CERVICAL: 78815

- A recent pathologic diagnosis of cervical cancer must have already been made before the FDG PET/CT scan is performed
- The results of a conventional imaging exam (CT or MRI) are negative for extra-pelvic metastasis

COLORECTAL: 78815

- Determine extent of regional and distant metastasis
- Evaluate for suspected recurrence in patients with serial rising CEA

ESOPHAGEAL: 78815

- Determine the extent of local, regional and distant metastasis for initial staging and restaging
- Detection of squamous cell carcinoma of esophagus prior to surgical resection

HEAD AND NECK: 78815

- Determine extent of local, regional, and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy
- Assist in restaging post surgical patients to determine recurrent/residual tumor

LUNG: 78815

- Distinguish malignant from benign pulmonary nodules
- Staging of regional and/or distant metastasis
- Detect recurrent/residual tumor following completion of a planned course of treatment

LYMPHOMA: 78815

- Determine extent of pretreatment disease
- Assess effectiveness of chemotherapy during the course of treatment
- Determine extent of disease following completion of a planned course of treatment

MELANOMA: 78816

- Identify extent of distant disease spread in patients with high risk melanoma or in suspected recurrence

MYELOMA: 78815

- Determine extent of local, regional and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy

OVARIAN: 78815

- Determine extent of local, regional and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy

PANCREAS: 78815

- Determine extent of local, regional and distant disease

SMALL CELL LUNG: 78815

- Determine extent of local, regional and distant disease

PET/CT

ADDITIONAL CLINICAL APPLICATIONS

Scheduling 000.000.0000

Company Name or Logo

ALL SOLID TUMORS: 78815

- Determine extent of local, regional and distant disease

STOMACH: 78815

- Determine extent of local, regional and distant disease

THYROID: 78815

- Determine extent of local, regional and distant disease
- Detect metastatic or locally recurrent disease in patients post thyroidectomy or radioiodine ablation with elevated thyroglobulin and negative I-131 examination

COMMON RADIATION TREATMENT PLANNING INDICATIONS

- Improve mapping of gross tumor volume for breast, head/neck and lung cancers

ONCOLOGY

OTHER: These previous non-covered indications are now reimbursed by Medicare

- All solid tumor types qualify for ONE pre-treatment scan, except prostate.
- Breast, cervical, colorectal, esophageal, head and neck, lymphoma, non-small cell lung, melanoma, myeloma, ovarian and thyroid cancers are covered for initial staging, monitoring response to treatment and restaging.
- Metastatic disease with an unknown primary tumor is covered for one initial treatment PET scan.
- All other malignancies may be scanned for monitoring treatment or restaging and are reimbursed by CMS when enrolled in the National Oncologic PET Registry.

CARDIOLOGY

MYOCARDIAL VIABILITY: 78459

- Determine the degree of viable myocardium prior to revascularization
- Aid in the pre-operative clinical evaluation of potential cardiac transplant cases

MYOCARDIAL PERFUSION [N-13 Ammonia or Rb-82]:

- Identify ischemic disease

NEUROLOGY

DEMENTIA: 78608

- Differentiate Alzheimer's disease from frontotemporal dementia

In patients with documented cognitive decline of at least six months and a recently established diagnosis of dementia who meet diagnostic criteria for both Alzheimer's disease (AD) and fronto-temporal dementia (FTD), who have been evaluated for specific alternate neurodegenerative diseases or causative factors, and for whom the cause of the clinical symptoms remains uncertain.

Additional conditions MUST be met, please contact your service provider.

EPILEPSY:

- Pre-surgical evaluation for the purpose of localization of a focus of refractory seizure activity

This information is not intended to replace or serve as a substitute for your duty to verify that such information is proper for your particular circumstance(s). In addition, due to the frequency that payer policies change, Alliance may have a gap between publication and/or effective dates of posted changes and modifications to this document. Therefore, it is recommended that you always refer to the modified date noted within this document to determine current relevance. The information provided herein references coverage determinations set forth by The Centers for Medicare and Medicaid Services (CMS). We strongly recommend that you always check with your local Medicare carriers and payer criteria as coverage varies by region and plan. Not all insurance payers follow Medicare's coverage criteria for PET/CT services. Additional Medicare coverage documentation can be found online at www.cms.hhs.gov/mcd/search.asp.

CMS Documents cited: AB-01-168, AB-02-026, AB-02-065, AB-03-092, A-03-076, CMS-1471-FC, Transmittal 156, 278 and 290, CAG#00088R, Transmittal 31, change request 3741.

The health information contained herein is provided for educational purposes only and is not intended to be medical advice or to replace discussions with a health care professional.

© Copyright 2007 Alliance Imaging, Inc. All rights reserved.

*Medicare codes as of 4/8/05